Healthcare Triangle
Healthcare Triangle's revenue rose 18.8% to $14 million in fiscal 2025. Its operating margin was −70.5%, down from −40.6% a year earlier. Free cash flow was −$17 million. The diluted share count rose 17427.8%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
What Healthcare Triangle does
Healthcare Triangle is a health care technology company. It helps hospitals, health systems, insurers, drug makers, biotech firms and medical device makers move their systems and data to public clouds such as Amazon Web Services, Google Cloud and Microsoft Azure, keep them secure and meet health privacy rules. It also installs, runs and supports electronic health record systems from vendors such as MEDITECH and Epic, and sells its own software: CloudEz and DataEz for cloud and data management, Readabl.ai for pulling information out of faxes and documents, Ziloy for mental wellness and Ezovion for running hospitals and clinics.
It reports three segments. Most revenue comes from staff doing project work and ongoing support. Software Services, which covers advice, setup and development, brought in $8.3 million in 2025, while Managed Services and Support, which covers support after setup and cloud hosting, brought in $5.4 million. Sales are concentrated: its top customer made up 20% of 2025 revenue and its top five 58%.
The company is based in Pleasanton, California. At the end of 2025 it had 43 full-time employees, 15 part-time employees and 26 subcontractors, and it relies on SecureKloud, an affiliate, for software development, sales support and other services. In June 2025 it bought Ezovion, a hospital software provider in Chennai, India.
Its biggest risks, as it describes them
- Losing one of the few customers that bring in most of its revenue.
- Competition from larger, better-funded technology and health care companies that could cut prices.
- Its reliance on SecureKloud, an affiliate, for essential services such as software development and staffing.
- Outages at the Amazon, Google and Microsoft data centers that host most of its platforms.
- A breach of the patient and personal health data it stores and handles for clients.
Income statement
Healthcare Triangle lost money in fiscal 2025: a net loss of $10 million.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 2 | 1 | 1 | 0 | 8 |
| Debt incl. finance leases | — | — | 5 | — | — |
| Net debt (negative means net cash) | — | — | 4 | — | — |
| Net debt to EBITDA | — | — | — | — | — |
| Debt to equity | — | — | — | — | — |
| Interest coverage | −9.4x | −77.0x | −8.0x | −39.3x | −17.3x |
| Current ratio | 1.9x | 1.2x | 0.7x | 0.2x | 1.0x |
| Quick ratio | 1.9x | 1.2x | 0.7x | 0.2x | 1.0x |
Cash flow
Projections
Project Healthcare Triangle's revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
Insider trades
No officer, director or 10% owner of Healthcare Triangle reported buying or selling its shares on the open market between November 20, 2025 and November 19, 2026.
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | — | — | — |
| Rule of 40 | −34.1% | — | −100.2% |
| Altman Z'' | −23.23 | −91.66 | −8.14 |
| Accruals ratio | −65.0% | −110.8% | 57.1% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Fail | Fail | Fail |
| Cash from operations is positive | Fail | Fail | Fail |
| Return on assets rose | Fail | Fail | Fail |
| Cash from operations exceeds net income | Pass | Pass | Fail |
| Debt fell relative to assets | — | — | — |
| Current ratio rose | Fail | Fail | Pass |
| Share count didn't rise | Fail | Pass | Fail |
| Gross margin rose | Pass | Pass | Fail |
| Revenue rose relative to assets | Pass | Fail | Pass |
| F-score | — | — | — |
Compare
Put Healthcare Triangle side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| Healthcare Triangle | FY25 | 18.8% | −70.5% | −119.0% | — | — | — | |
| Zhongchao | FY25 | −28.3% | −54.4% | 6.1% | — | — | — | Compare |
| SOPHiA GENETICS | FY25 | 18.6% | −91.8% | −47.2% | −207.1% | — | 2 | Compare |
| OptimizeRx | FY25 | 18.8% | 10.7% | 17.1% | 6.4% | 0.2x | 8 | Compare |
| CareCloud | FY25 | 8.7% | 9.4% | 19.7% | 21.5% | −0.1x | 5 | Compare |
6 years of figures
| Fiscal year | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|
| Income statement | ||||||
| Revenue | 31 | 35 | 46 | 33 | 12 | 14 |
| Revenue growth | — | 12.5% | 30.1% | −27.6% | −64.8% | 18.8% |
| Gross profit | 9 | 10 | 11 | 1,070 | 1,070 | — |
| Research and development | 2 | 5 | 8 | 1 | 0 | 0 |
| Operating income | 1 | −5 | −16 | −8 | −5 | −10 |
| Net income | 2 | −6 | −14 | −9 | −6 | −10 |
| Diluted EPS (US$) | 0.08 | −0.20 | −3.88 | −2.08 | — | — |
| Diluted shares (millions) | 28 | 29 | 4 | 4 | 0 | 0 |
| Cash flow | ||||||
| Cash from operations | −1 | −7 | −5 | −2 | −1 | −16 |
| Capital expenditure | — | — | 0 | 0 | — | 0 |
| Free cash flow | — | — | −5 | −2 | — | −17 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 0 | 0 | 0 | 0 |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock-based compensation | — | 0 | 0 | 0 | 0 | 0 |
| Balance sheet at fiscal year end | ||||||
| Cash and short-term investments | 1 | 2 | 1 | 1 | 0 | 8 |
| Debt incl. finance leases | — | — | — | 5 | — | — |
| Total assets | 11 | 25 | 13 | 7 | 2 | 23 |
| Total liabilities | 7 | 8 | 7 | 8 | 7 | 13 |
| Shareholders' equity | 4 | 14 | 6 | −1 | −5 | 10 |
| Margins and ratios | ||||||
| Gross margin | 27.4% | 29.8% | 24.6% | 3,222.6% | 9,148.4% | — |
| Operating margin | 3.8% | −15.2% | −35.6% | −23.2% | −40.6% | −70.5% |
| Net margin | 7.5% | −16.9% | −31.3% | −26.2% | −51.0% | −68.2% |
| Free cash flow margin | — | — | −11.8% | −6.5% | — | −119.0% |
| Rule of 40 (growth + FCF margin) | — | — | 18.4% | −34.1% | — | −100.2% |
| Return on capital | — | — | — | — | — | — |
| Return on equity | — | −64.1% | −141.6% | −373.7% | — | −392.4% |
| Return on assets | — | −33.3% | −75.8% | −86.3% | −135.4% | −76.7% |
| Net debt to EBITDA | — | — | — | — | — | — |